OneSource Specialty Pharma Ltd

OneSource Specialty Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 June 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

OneSource Specialty Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent uptick in price, key technical indicators present a complex picture that warrants close attention from investors and market analysts alike.

OneSource Specialty Pharma Ltd has seen its investment rating downgraded from Hold to Sell as of 26 May 2026, reflecting a combination of deteriorating technical indicators, weak financial trends, and valuation concerns. Despite some long-term growth in sales, the company’s overall quality and ability to generate shareholder returns have come under scrutiny, prompting a reassessment of its market prospects.

OneSource Specialty Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a recent downgrade in daily moving averages and a slight dip in price, the stock’s weekly and monthly technical indicators present a complex picture that investors should carefully analyse.

OneSource Specialty Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators and financial trends despite ongoing valuation concerns and management challenges. The revised Mojo Score of 51.0 signals cautious optimism amid mixed signals from quality metrics and market performance.

OneSource Specialty Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector.

OneSource Specialty Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock’s technical indicators present a complex picture, with bullish signals on some fronts and bearish or neutral cues on others, reflecting a period of consolidation and cautious investor sentiment.

OneSource Specialty Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 May 2026, providing investors with the latest insights into the company’s performance and outlook.

OneSource Specialty Pharma Ltd has reported a flat financial performance for the quarter ended March 2026, marking a notable improvement from previous negative trends. Despite achieving its highest quarterly net sales to date, the company faced significant pressure on profitability, with a sharp decline in net profit after tax (PAT) signalling ongoing challenges in margin management.

OneSource Specialty Pharma Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹20,747 crores, reported a dramatic 95.33% year-on-year decline in consolidated net profit to ₹4.60 crores for Q4 FY26, despite achieving modest revenue growth. The stock has declined 2.34% following the results announcement, reflecting investor concerns over profitability erosion even as the company managed to recover from the previous quarter's substantial losses.

OneSource Specialty Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish weekly indicators, the stock’s daily moving averages and relative strength index (RSI) suggest caution for investors as price momentum shows signs of weakening.

OneSource Specialty Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a strong day change of 4.24%, the stock’s technical indicators present a complex picture, with bullish signals on weekly MACD and Bollinger Bands contrasting with bearish RSI and mildly bearish daily moving averages. This nuanced technical landscape warrants close attention from investors navigating the Pharmaceuticals & Biotechnology sector.

OneSource Specialty Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 May 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 06 May 2026, providing investors with the latest view of the company’s position.

OneSource Specialty Pharma Ltd has experienced a notable shift in its technical parameters, moving from a mildly bullish to a mildly bearish trend. Despite a modest day gain of 0.97%, the stock’s technical indicators present a complex picture, with some signals suggesting caution for investors amid evolving price momentum.